Lupin CEO On ProAir Generic Site Transfer, Digital Plans
Amazon Entry Not A Near-term Worry
Executive Summary
Lupin CEO Vinita Gupta shares plans to shift manufacture of albuterol and some other products to its US facilities, with a rollout of a generic to Teva’s ProAir expected soon. Enthused by Lupin’s first biosimilar introduction In Europe with etanercept and looking to up the company’s digital game, the executive says Amazon’s entry into India’s e-pharmacy space is not a near-term worry
You may also be interested in...
Perrigo’s Loss Is Lupin’s Gain
Having gained from Perrigo’s withdrawal of generic ProAir (albuterol sulphate), Lupin plans to ramp up capacity by Q4 as demand is seen rising on account of flu and COVID-29 cases in the US. Meanwhile, FDA observations at its Somerset facility are a dampener
Strides Readies SteriScience For Injectables Push
Strides is expanding its presence in synthetic injectables via a new company, SteriScience, while keeping its biologics injectables business under Stelis. A head start with existing IP assets and those from a new joint venture with Brooks Labs will enable the fledgling firm to file its first ANDA in fiscal 2021, with break-even foreseen in two years.
Double Dose: After Stelis, Strides Readies SteriScience For Injectables Push
Strides is expanding its presence in synthetic injectables via a new company, SteriScience, while keeping its biologics injectables business under Stelis. A head start with existing IP assets and those from a new joint venture with Brooks Labs will enable the fledgling firm to file its first ANDA in fiscal 2021, with break-even seen in two years.
Need a specific report? 1000+ reports available
Buy Reports